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Catechol-O-methyltransferase (COMT) is a key enzyme in the elimination of dopamine in the prefrontal cortex of
the human brain. Genetic variation in the COMT gene (MIM 116790) has been associated with altered prefrontal
cortex function and higher risk for schizophrenia, but the speciﬁc alleles and their functional implications have
been controversial. We analyzed the effects of several single-nucleotide polymorphisms (SNPs) within COMT on
mRNA expression levels (using reverse-transcriptase polymerase chain reaction analysis), protein levels (usingWest-
ern blot analysis), and enzyme activity (using catechol methylation) in a large sample (n p 108) of postmortem
human prefrontal cortex tissue, which predominantly expresses the -membrane-bound isoform. A common coding
SNP, Val158Met (rs4680), signiﬁcantly affected protein abundance and enzyme activity but not mRNA expression
levels, suggesting that differences in protein integrity account for the difference in enzyme activity between alleles.
A SNP in intron 1 (rs737865) and a SNP in the 3′ ﬂanking region (rs165599)—both of which have been reported
to contribute to allelic expression differences and to be associated with schizophrenia as part of a haplotype with
Val—had no effect on mRNA expression levels, protein immunoreactivity, or enzyme activity. In lymphocytes from
47 subjects, we conﬁrmed a similar effect on enzyme activity in samples with the Val/Met genotype but no effect
in samples with the intron 1 or 3′ SNPs. Separate analyses revealed that the subject’s sex, as well as the presence
of a SNP in the P2 promoter region (rs2097603), had small effects on COMT enzyme activity. Using site-directed
mutagenesis of mouse COMT cDNA, followed by in vitro translation, we found that the conversion of Leu at the
homologous position into Met or Val progressively and signiﬁcantly diminished enzyme activity. Thus, although
we cannot exclude a more complex genetic basis for functional effects of COMT, Val is a predominant factor that
determines higher COMT activity in the prefrontal cortex, which presumably leads to lower synaptic dopamine
levels and relatively deleterious prefrontal function.
Introduction
Since its discovery in 1958 (Axelrod and Tomchick 1958),
catechol-O-methyltransferase (COMT) has been an im-
portant enzyme in catecholamine biochemistry and phar-
macology and, more recently, in genetic mechanisms of
variation in catechol metabolism and its clinical impli-
cations. COMT catalyzes the transfer of a methyl group
from S-adenosyl-methionine (SAM) to a hydroxyl group
on a catechol nucleus (e.g., dopamine, norepinephrine, or
catechol estrogen) (Weinshilboum et al. 1999). Genetic
variation in COMT has been associated with diverse clin-
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ical phenotypes, from anxiety to estrogen-related cancer
(Enoch et al. 2003; Ahsan et al. 2004), and it has been
studied particularly extensively in relation to risk for
schizophrenia (Harrison and Weinberger 2004). The
COMT gene is located in chromosome 22q11, one of the
principal loci linked to schizophrenia (Badner and Ger-
shon 2002), and in the DiGeorge–velocardiofacial syn-
drome hemideletion. There are two promoters, P1 and
P2, (Tenhunen et al. 1993), that control transcription of
two different mRNAs. A longer mRNA from the P2 pro-
moter encodes mainly a membrane-bound COMT (MB-
COMT), and a shorter mRNA from the P1 promoter
encodes a soluble COMT (S-COMT). The MB-COMT
has higher substrate afﬁnity but lower catalytic activity
than S-COMT (Lotta et al. 1995). The MB-COMT is
predominantly expressed in brain neurons (Matsumoto
et al. 2003), and S-COMT is predominantly expressed in
other tissues, such as liver, blood, and kidney (Tenhunen
et al. 1993; Lundstrom et al. 1995). Human COMT con-
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tains a common functional polymorphism, a GrA sub-
stitution in exon 4 that alters the amino acid codon at
position 108 (Val108Met) (rs165688) in S-COMT or po-
sition 158 (Val158Met) in the MB-COMT protein (Lotta
et al. 1995). This common polymorphismhas been shown
to result in a signiﬁcant change in enzyme activity in pe-
ripheral blood and in liver (Scanlon et al. 1979; Wein-
shilboum and Dunnette 1981; Boudikova et al. 1990;
Lotta et al. 1995).
Although COMT is expressed widely throughout the
brain, it appears to play a particularly important role
in dopamine ﬂux in the prefrontal cortex. In the cortex,
the dopamine transporter, which has a 1,000-fold higher
afﬁnity for dopamine than does COMT, is expressed at
very low levels and does not appear to affect extracel-
lular dopamine levels (Garris et al. 1993; Sesack et al.
1998; Lewis et al. 2001; Huotari et al. 2002b). Thus,
inactivation of dopamine in the prefrontal cortex ap-
pears to rely preferentially on catabolic enzymes, in-
cluding COMT. This notion is supported by pharma-
cological evidence (Garris et al. 1993; Tunbridge et al.
2004a) and by studies that found that dopamine tissue
levels (Gogos et al. 1998) or turnover (Huotari et al.
2002a) were signiﬁcantly increased in the frontal cortices
but not in the striata of COMT knockout mice, as com-
pared with wild-type mice. Also, COMT mRNA ex-
pression in the prefrontal cortex of the human brain
appears to be greater than in the striatum (Matsumoto
et al. 2003). Given the established role of prefrontal
dopamine in working memory (Goldman-Rakic et al.
2004), it is not surprising that COMT would play a
role in prefrontally mediated cognitive function. Indeed,
clinical studies of COMT have revealed that the Met
allele, which encodes the enzyme with lower activity, is
associated with better performance on tests of prefron-
tally mediated cognition (Egan et al. 2001; Goldberg
et al. 2003; Mattay et al. 2003; Diamond et al. 2004;
Nolan et al. 2004). The effect of the Val/Met polymor-
phism on dopamine-mediated frontal cortical function
may be the neurobiological mechanism behind the clin-
ical associations with CNS disorders (Weinberger et al.
2001).
Most studies of COMT enzyme activity have focused
on the effect of the Val/Met polymorphism at the 108th/
158th codon. The Val allele encodes an enzyme with
higher stability at a variety of temperatures from 37C
to 56C (Scanlon et al. 1979; Spielman and Weinshil-
boum 1981; Weinshilboum and Dunnette 1981; Lotta et
al. 1995). However, the actual difference in enzyme ac-
tivity between the Val and Met proteins is controversial:
different temperatures were used for testing enzyme sta-
bility, and high variations were observed among the
various samples tested (Scanlon et al. 1979; Spielman and
Weinshilboum 1981; Weinshilboum and Dunnette 1981;
Lotta et al. 1995). The high variations raise the possibility
that theremight be other SNPs that affect enzymeactivity.
Indeed, other SNPs in COMT, particularly a SNP in in-
tron 1 (rs737865) of the MB-COMT isoform and a SNP
in the 3′ ﬂanking region (rs165599), have been reported
to be associated with risk for schizophrenia and possibly
to affect COMT expression (Shifman et al. 2002). Bray
et al. (2003) suggested, on the basis of evidence of dif-
ferential expression of Val and Met chromosomes, that
these other SNPs may represent cis elements that have
greater effects on enzyme activity than the Val/Met poly-
morphism. Another SNP in the 5′ ﬂanking region
(rs2097603)—and potentially contained within the P2
promoter—has been proposed as a functional SNP; link-
age disequilibrium (LD) analysis suggests that this SNP
may account for the association of the intron 1 SNP with
schizophrenia (Palmatier et al. 2004). However, it is un-
known whether any variation in COMT, other than Val/
Met, affects protein integrity or enzyme activity. In ad-
dition, COMT activity in human dorsolateral prefrontal
cortex (DLPFC), a brain region critical to cognitive func-
tion and presumably especially impacted by COMT ac-
tivity, has never been examined.
In this study, we analyzed samples of human post-
mortem DLPFC and human lymphocytes to examine the
effects of SNPs implicated in schizophrenia on COMT
enzyme activity. We also measuredCOMT gene and pro-
tein expression in the brain samples. The intent of this
study was to test for potential functional effects of these
SNPs. Thus, functional SNPs in the P2 promoter region
and SNPs reﬂecting cis-acting factors might be expected
to particularly affect mRNA abundance, consistent with
the data of Bray et al. (2003). In contrast, the coding Val/
Met SNP might be expected to have a greater impact on
protein integrity (Shield et al. 2004). For any of these
genetic mechanisms to penetrate to the level of clinical
phenotype, an effect on enzyme activity would be ex-
pected. Our results demonstrate that the enzyme activity
of COMT-Val is ∼40% higher than that of COMT-Met
in postmortem human DLPFC at 37C, a normal phys-
iological temperature, and that an analogous effect on
the level of protein immunoreactivity is evident for the
COMT-Val variant. The P2 promoter SNP may have a
small effect on COMT expression, as reﬂected in enzyme
activity in lymphocytes, whereas the intron 1 and 3′ ﬂank-
ing SNPs have no signiﬁcant effects on COMT mRNA
expression, protein immunoreactivity, or enzyme activity
in the human DLPFC or on enzyme activity in lympho-
cytes. A comparison of human and mouse COMT con-
ﬁrms that the amino acid at the Val/Met locus is impor-
tant for COMT activity and suggests that COMTactivity
has decreased during the course of evolution. These re-
sults suggest that the Val/Met SNP is the predominant
genetic factor that determines COMT activity in human
DLPFC and its effect on prefrontal dopamine signaling.
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Material and Methods
Human Postmortem Tissue
Postmortem DLPFC tissue (one hemisphere) from 108
brains was collected at the Clinical Brain Disorders
Branch, National Institute of Mental Health (NIMH),
from 77 normal controls (19 females, 58 males; 26
whites, 51 African Americans; mean age 40.6  14.9
years; postmortem interval [PMI] 30.7  13.6 h; pH
6.60 0.24) and 31 individuals with schizophrenia (11
females, 20 males; 15 whites, 16 African Americans;
mean age 45.9  15.4 years; PMI 37.1  14.8 h; pH
6.47  0.24). Informed consent of the next of kin was
obtained as described in detail elsewhere (Kleinman et
al. 1995), in accordance with a protocol approved by
the NIMH institutional review board. The tissues were
pulverized and stored at 80C. The brains were se-
lected from a large pool of postmortem specimens in an
effort to optimize mRNA and protein quality without
prior knowledge of COMT genotypes. Cases with his-
tories of other psychiatric or neurological disorders or
of substance abuse were excluded from the normal con-
trol series. Demographic characteristics of this cohort,
including causes of death, are shown in table A1 (online
only). In general, the cohort characteristics, such as PMI,
pH, and age, are similar to those in our previous studies
(e.g., Matsumoto et al. 2003; Halim et al. 2003); al-
though samples in our cohort have higher mean pH val-
ues in comparison with another study of COMTmRNA
expression (Tunbridge et al. 2004b), the cases are similar
in terms of PMI and age. The only other study of brain
COMT mRNA expression (Bray et al. 2003) did not
provide information about pH or PMI.
Protein Extraction
DLPFC (50–130 mg) tissue samples were homoge-
nized in a protease inhibitor-Tris-glycerol extraction buf-
fer (0.024% AEBSF, 0.005% aprotinin, 0.001% leu-
peptin, 0.001% pepstatin A, 50% glycerol, and 0.6%
Tris) (1 g tissue:10 mL buffer) (Halim et al. 2003). The
samples were then aliquoted and stored at 80C. Pro-
tein concentration was determined by use of the Brad-
ford assay.
RNA Extraction
Total RNA was extracted from ∼300 mg of tissue by
use of the TRIzol reagent (Life Technologies), as de-
scribed elsewhere (Hashimoto et al. 2004). The yield of
total RNA was determined by absorbance at 260 nm.
RNA quality was assessed with high-resolution capillary
electrophoresis (Agilent Technologies), and only samples
showing clearly deﬁned, sharp 18S and 28S ribosomal
peaks and 28S:18S ratios 11.2 were included. Total
RNA (4 mg) was used in 50 ml of a reverse transcriptase
reaction to synthesize cDNA by use of a SuperScript
First-Strand Synthesis System for RT-PCR (Invitrogen),
in accordance with the manufacturer’s protocol.
Immunoblotting
Homogenates of tissue samples from normal controls
( ) containing 1.5 mg of total protein content pernp 73
5 ml were prepared for immunoblotting by diluting the
homogenized samples with water and adding LDS sam-
ple buffer (1.25 ml of 4# buffer per sample) (Invitrogen).
Samples were then heated to 90C for 5 min to denature
proteins. For each sample, 5 ml were loaded onto precast
10% Bis-Tris polyacrylamide gels (Invitrogen), and pro-
teins were separated by electrophoresis at 175 V for 0.5
h by use of a single power source. Each gel contained a
molecular-weight marker ladder (SeeBlue Plus 2 [Invi-
trogen]) and pooled samples from controls, which were
used for normalization in triplicate. Seven separate gels
were used in one experiment. Gels were transferred onto
nitrocellulose membranes for 2 h at room temperature
at 85 V in NuPAGE transfer buffer with 20%methanol.
Membranes were blocked for 1 h in 10% goat serum in
Tris-buffered saline (TBS) with 0.1% Tween-20 (TBS-T)
and then were incubated with the polyclonal rabbit anti-
COMT antibody (1:7,000 dilution [Chemicon]) and a
monoclonal mouse anti-actin antibody (1:3,000 dilution
[Chemicon]). Blots were rinsed in TBS-T, incubated in
a peroxidase-conjugated goat anti-rabbit and goat anti-
mouse antibody (1:10,000 dilution [Chemicon]) for 2
h in 5% normal goat serum in TBS-T and rinsed in TBS-
T. Blots were developed in ECL Plus (Amersham) and
were exposed to Kodak BioMax ﬁlm. Films were digi-
tized using a scanner, and the resulting images were an-
alyzed using National Institutes of Health Image gel
plotting macros on a Macintosh computer (G4). The
values for all samples were expressed as a percentage of
a mean of controls on the same gel.
Human Lymphocytes
Blood was collected from normal subjects, and lym-
phocytes were transformed into lymphoblast cultures by
standard methods. Lymphocytes were selected from 47
individuals who were homozygous at the Val/Met locus,
and the samples were matched by sex. The methods for
recruitment and screening of volunteers are described in
detail elsewhere (Egan et al. 2001). The DNA collection
protocol was approved by the NIMH institutional re-
view board, and all donors gave informed consent. Low-
speed centrifugation was used to collect 100,000,000
cells. The cell pellets were lysed in 300 ml of 1# lysis
buffer (5 mM Tris-HCl [pH 7.4], 0.2% Triton X-100,
and 1 mM dithiothreitol [DTT]) with a sonicator. The
total protein concentrations of the lysates weremeasured
810 Am. J. Hum. Genet. 75:807–821, 2004
by the Bradford method. Immunoblotting from lympho-
cytes was performed using the method described above.
Real-Time Quantitative PCR
COMT mRNA expression levels in brain were mea-
sured by real-time quantitative RT-PCR by use of an
ABI Prism 7900 sequence detection system with 384-
well format. TaqMan probes and primers spanning ex-
ons 5–6 were purchased from Applied Biosystems (As-
say-on-Demand [catalog number Hs_00241349m1]).
Each 20 ml PCR contained 6 ml of cDNA, 1 ml of 20#
primer/probe mixture, and 10 ml of RT-PCRMasterMix
Plus (Eurogentec) containing Hot GoldStar DNA poly-
merase, dNTPs with dUTP, uracil-N-glycosylase, passive
reference, and optimized buffer components. PCR cy-
cling conditions were 50C for 2 min, 95C for 10 min,
40 cycles of 95C for 15 s, and 59C or 60C for 1 min.
PCR data were obtained with the Sequence Detection
Software (SDS, version 2.0 [Applied Biosystems]) and
quantiﬁed by a standard curve method by use of serial
dilutions of pooled cDNA derived from RNA obtained
from DLPFC of 12 normal control subjects. SDS plotted
real-time ﬂuorescence intensity. The threshold was set
within the linear phase of the amplicon proﬁles. All mea-
surements were performed in triplicate.
SNP Genotyping
All genotypes were determined using the 5′ exonucle-
ase TaqMan assay. The sequences of primers and Taq-
Man probes for the SNP genotyping were as follows:
(1) P2 promoter SNP (rs2097603), GCCGTGTCTGGA-
CTGTGAGT (forward)/GGGTTCAGAATCACGGAT-
GTG (reverse) and 6FAM-AACAGACAGAAAAGTTT-
CCCCTTCCCA/VIC-CAGACAGAAAAGCTTCCCC-
TTCCCATA; (2) intron 1 SNP (rs737865), GCTTGGA-
GGGTCACTTTAAACAATA (forward)/TGCTAACA-
GACCTGCTTTTTGG (reverse) and 6FAM-CAGGAC-
ACAAAAAcCCCTGGCTG/VIC-CAGGACACAAAA-
AtCCCTGGCTGG; (3) Val/Met SNP (rs4680), TCGA-
GATCAACCCCGACTGT (forward)/AACGGGTCAG-
GCATGCA (reverse) and 6FAM-CCTTGTCCTTCAC-
GCCAGCGA/VIC-ACCTTGTCCTTCATGCCAGCG-
AAAT; (4) 3′ ﬂanking SNP (rs165599), CAGCCACAG-
TGGTGCAGAG (forward)/AAGGTGTGAATGCTG-
GCTGA (reverse) and 6FAM-TTTCCCAGGCtGGCA-
GTCGTC/VIC-CGTTTCCCAGGCcGGCAGT.
Site-Directed Mutagenesis of Mouse COMT cDNA
Mutations from mouse Leu codon (CTA) to human
Val codon (GTG) or Met codon (ATG) were introduced
into mouse COMT cDNA (acquired from the Mam-
malian Gene Collection [see the Mammalian Gene Col-
lection Web site]) by PCR-based site-directed mutagen-
esis (Ailenberg and Silverman 1997). Primers containing
mutations at the Leu site were synthesized and incor-
porated into mouse COMT cDNA by PCR. The primers
for synthesis of the mouse COMT-Met and COMT-Val
mutants in the ﬁrst round of PCRwereGATGCTGTTG-
GCTGCTGTCTCA (forward)/CTGCATGCCTGCGA-
AGTCCAGCATTTG (reverse) and GAAATGCTGGA-
CTTCGCAGGCATGCAG (forward)/GCACTGTGAT-
CTACTGCATCTCT (reverse) for the COMT-Met mu-
tant and GATGCTGTTGGCTGCTGTCTCA (for-
ward)/CTGCACGCCTGCGAAGTCCAGCATTTG
(reverse) and CAAATGCTGGACTTCGCAGGCGTG-
CAG (forward)/GCACTGTGATCTACTGCATCTCT
(reverse) for the COMT-Val mutant. The PCR products
that contain the speciﬁc mutations were used as tem-
plates for the second round of PCR with speciﬁc primers
(CGTAATACGACTCACTATAGGGCGACCCACCA-
TGGGTGGCACAAAGGAGCA [forward]/GCACTG-
TGATCTACTGCATCTCT [reverse]), which ampliﬁed
the mutant mouse COMT cDNA and incorporated a T7
promoter to the 5′ end of the full length of mouse COMT
cDNAs. The PCR products from the second-round PCR
were puriﬁed using a PCR product puriﬁcation kit (Qia-
gen) and were used as templates for in vitro synthesis
of mouse mutant COMT proteins.
In Vitro Translation
Full-length MB human COMT-Val, COMT-Met, and
mouseCOMT-Leu cDNAswere obtained from theMam-
malian Gene Collection (seeMammalian Gene Collection
Web site). The DNA templates for in vitro translation
were prepared by PCR with speciﬁc forward primers that
contained the T7 promoter and the backward primers.
The DNA templates were puriﬁed using a PCR product
puriﬁcation kit (Qiagen). Human andmouse COMTpro-
teins were translated from the templates by use of an in
vitro transcription-coupled protein translation kit (Pro-
mega), and enzyme activity of the translated COMT was
measured.
Modiﬁed COMT Activity Assay
The COMT enzyme activity assay uses the organic sol-
vent extraction method that separates the radioactive
product, the methylated catechol, and the free radioactive
coenzyme, 3H-SAM (Zurcher and Da Prada 1982). From
each sample, 100 mg of human DLPFC or lymphocyte
protein at a concentration of 5 mg/ml was transferred to
a fresh microcentrifuge tube and equilibrated to room
temperature shortly before the enzyme assay. To each
tube, we added 500 ml of the substrate mixture, which
contained 10 mM Tris (pH 7.4), 1 mM MgCl2, 1.5 mCi
of 3H-SAM, 10 mM of catechol, and 1 mM of DTT. The
tubes were then incubated at 37C for 20 min. The re-
actions were immediately terminated by the addition of
500 ml of 1M HCl. The radioisotope-labeled catechol
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Table 1
Relationships in Brain with Age, PMI, and pH
MEASUREMENT
SPEARMAN’S
CORRELATION
COEFFICIENT (r) FOR
Age PMI pH
COMT enzyme activity (DLPFC) .194a .141 .151
S-COMT immunoreactivity .085 .023 .077
MB-COMT immunoreactivity .297b .006 .091
COMT mRNA levels .112 .016 .097
a .P ! .05
b .P ! .01
products from the reactions were extracted by adding 10
ml of scintillation ﬂuid (Flow I [Molecular Diagnosis]) to
the reaction mixture and then were measured for the ra-
dioactivity of the mixture in a scintillation counter. The
relative COMT enzyme activity is presented as disinte-
grations per minute (DPM) per mg total protein. To es-
tablish a baseline control for nonspeciﬁc reactions that
do not depend on COMT, 5 ml of the speciﬁc COMT
inhibitor, tolcapone (10 mg/ml), was added to a tube con-
taining 100 mg of the human DLPFC sample. The high
concentration of potent inhibitor blocked the speciﬁc re-
action catalyzed by COMT, and the radioactivity from
this reaction served as a baseline. To determine COMT
activity in the in vitro–translated protein samples, the rel-
ative COMT activity was normalized with the levels of
35S-labeled COMT protein products. A time-course anal-
ysis of COMT stability was prepared by either treating
protein samples at 37C (heat-treated) or keeping them
on ice (cold-treated) for 0–120 min; the COMT activity
in the heat-treated and cold-treated samples was then
measured to establish stability.
Statistical Analysis
Two-tailed Student’s t tests were used to examine
whether diagnostic groups (normal controls and individ-
uals with schizophrenia) differed in variables such as brain
pH, PMI, and age. Separate two-tailed Student’s t tests
were also used to test whether mRNA expression levels,
protein levels, and enzyme activity differed between the
two groups (normal controls and individuals with schizo-
phrenia). Spearman’s coefﬁcients of correlation were cal-
culated to examine whether enzyme activity correlated
with protein immunoreactivity or mRNA expression or
whether these measurements were associated with age,
pH, or PMI. In the case of signiﬁcant correlations, one-
way analyses of covariance (ANCOVAs) were performed
covarying for a correlated factor. To test the effects of sex
or race on dependent measures, two-way analyses of var-
iance (ANOVAs) were used with diagnosis (controls or
individuals with schizophrenia) or genotype and sex as
independent factors. One-way ANOVAs, followed by
Fisher’s protected least signiﬁcant difference post hoc
tests, when appropriate, were used to test the effects of
genotype on enzyme activity, protein immunoreactivity,
and COMT mRNA expression. To control for possible
effects on enzyme activity of genotype at one locus related
to LD with another locus, analyses were also performed
conditioned on homozygote backgrounds at each locus.
Results
COMT mRNA Expression in Brain by RT-PCR
mRNA expression levels (either without normali-
zation or normalized by b-2-microglobulin or b-actin)
were not signiﬁcantly correlated with age, pH, or PMI
( ; ) (table 1). There was no effect of diseaser ! 0.1 P 1 .05
on COMT mRNA expression normalized by b-2-mi-
croglobulin or b-actin ( [110 df]; ) or ont ! 1.5 P 1 .5
the expression of b-2-microglobulin or b-actin mRNAs
( [110 df]; ). There were no signiﬁcant dif-t ! 1.0 P 1 .5
ferences between the genotypic groups in the expression
of both reference genes, b-2-microtubulin and b-actin
( ), and none of the genotypes examined (Val/Met,P 1 .2
P2 promoter, the intron 1 SNP, or the 3′ SNP) signiﬁ-
cantly affected COMTmRNA expression normalized by
b-2-microglobulin or b-actin ( ) (table 2), in eitherP 1 .5
of the clinical groups or in the entire sample.
COMT Immunoreactivity
Immunoblotting analysis of DLPFC samples revealed
that COMT proteins migrated with a double band ap-
proximately at the predicted molecular weights of 25
kDa and 28 kDa, corresponding to the soluble and MB
forms of COMT, respectively (ﬁg. 1). The band corre-
sponding to MB-COMT was markedly more prominent
than that corresponding to S-COMT. There was a sig-
niﬁcant effect of the Val/Met genotype on immunoreac-
tivity of the S-COMT isoform ( ;F[2,71]p 5.96 P !
) (table 2). Individuals with the Met/Met genotype.01
showed 54% less S-COMT immunoreactivity than in-
dividuals with the Val/Val genotype ( ) and 21%Pp .001
less than individuals with the Val/Met genotype (Pp
). Although there was only a trend effect of geno-.02
type on MB-COMT immunoreactivity ( ;F[2,71]p 2.25
) (table 2), post hoc testing revealed that—likePp 0.09
S-COMT—individuals with the Met/Met genotype
showed signiﬁcantly lower immunoreactivity than sub-
jects with the Val/Val genotype ( ). S-COMT andPp .03
MB-COMT immunoreactivities were highly correlated
with each other ( ; ). Although therer 1 0.7 P ! .0001
were no signiﬁcant correlations of S-COMT or MB-
COMT immunoreactivity with pH or PMI ( ;r ! 0.1
) and no correlation of S-COMT with age (P 1 .1 r !
; ), there was a positive correlation of MB-0.1 P 1 .1
COMT with age ( ; ) (table 1). Reanalysisr 1 0.2 P ! .01
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Figure 1 Effect of the Val/Met SNP on S-COMT and MB-
COMT protein immunoreactivity. A, Comparison of protein immu-
noreactivity (analyzed by Western blotting with the use of a speciﬁc
anti-human COMT antibody) for S-COMT and MB-COMT proteins
in postmortem DLPFC tissues with genotypes Val/Val, Val/Met, and
Met/Met. The asterisk (*) indicates difference from Val/Val at a sig-
niﬁcance level of . B, A representative Western blotting imageP ! .05
with MB-COMT, S-COMT, and internal control (Actin) bands.
Table 2
Effects of Genotype, Sex, and Race
MEASUREMENT
F VALUE FOR
Genotype
Haplotype Sex RaceVal/Met P2 Promoter 3′ SNP Intron 1 SNP
COMT enzyme activity (DLPFC) 7.95a 1.47 1.70 .57 2.24 3.96b .04
COMT enzyme activity (lymphocytes) 16.29a 7.31c .02 3.37b NAd 2.18 NAe
S-COMT immunoreactivity 5.96c .65 .53 .61 1.11 .07 .86
MB-COMT immunoreactivity 2.25f .89 .70 1.28 .55 .34 .50
COMT mRNA levels .10 2.10 .77 .99 .11 1.05 .26
NOTE.—The table displays the results of one-way ANOVAs. NA p not applicable.
a .P ! .001
b .P ! .05
c .P ! .01
d Data unavailable because groups were small.
e Only whites were tested.
f .Pp .09
of the effect of genotype on MB-COMT protein im-
munoreactivity, covarying for age, revealed a similar ef-
fect ( ; ). There was no signiﬁcantF[2,71]p 2.1 Pp .1
effect of any other genotype on S-COMT orMB-COMT
immunoreactivity, either in the entire sample or in sub-
groups homozygous for Val or Met ( ) (table 2)P 1 .2
The effects of sex on S-COMT and MB-COMT im-
munoreactivity were not signiﬁcant ( ; ) (ta-F ! 0.5 P 1 .4
ble 2). There was no correlation between either S-COMT
or MB-COMT and the expression of COMT mRNA
( ; ).r ! 0.1 P 1 .5
Effects of Val/Met on COMT Activity in Human DLPFC
at 37C
Our assay showed a linear relationship betweenCOMT
enzyme activity and total protein concentration across a
wide range (ﬁg. 2A), which suggests that we can detect
differences in COMT activity among humanDLPFC sam-
ples with large differences in enzyme activity. Under nor-
mal physiological temperatures without heat pretreat-
ment, the activity of homozygous COMT-Val was ∼38%
higher than that of homozygous COMT-Met in the
DLPFC ( ; ) (ﬁg. 2B). This dif-F[2,102]p 7.95 P ! .001
ference in enzyme activity between Val andMet is smaller
than the 2–4-fold difference reported elsewhere by several
other groups; it may reﬂect the lower temperatures used
in our study, confounders associated with postmortem
tissue, or differences in assay methodology. Enzyme ac-
tivity was positively, although weakly, correlated with age
( ; ) (table 1). We therefore reanalyzed therp 0.19 P ! .05
effect of the Val/Met genotype on enzyme activity co-
varying for age, and the effect was still highly signiﬁcant
(ANCOVA ; ). The effect of theF[2,102]p 6.4 P ! .01
Val/Met polymorphism on COMT activity was conﬁrmed
in lymphoblast cultures ( ; )F[1,45]p 16.288 P ! .001
(ﬁg. 2C), where the effect size of the difference was com-
parable with that of DLPFC, suggesting that the observed
effect of the Val/Met polymorphism in brain was not due
to confounders of postmortem tissues.
The enzyme activity in DLPFC was signiﬁcantly cor-
related with both S-COMT and MB-COMT immuno-
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Figure 2 Signiﬁcantly higher activity of COMT-Val than of COMT-Met in human DLPFC tissue and in lymphocytes at 37C. A, High
correlation of the relative COMT activity with protein concentration ( ) in a linear relationship. B, COMT activity in protein samplesrp 0.999
from human postmortem DLPFC tissues with genotypes Val/Val, Val/Met, and Met/Met. C, COMT activity in protein samples from lymphoblast
cultures from subjects with genotypes Val/Val and Met/Met. Np sample size. Two asterisks (**) indicate difference from Val/Val at a signiﬁcance
level of .P ! .01
reactivities ( ; ). To examine whether the ef-r 1 0.4 P ! .01
fect of the Val/Met genotype on enzyme activity was at
least in part independent of its effect on the integrity of
the protein, we used MB-COMT immunoreactivity as a
covariate in the analyses and found that the effect of ge-
notype was still signiﬁcant ( ; ).F[2,67]p 4.12 P ! .02
This suggests that differences in the abundance or integrity
of COMT protein, per se, do not account for the entire
difference in enzyme activity between individuals with
different Val/Met genotypes. We also analyzed the effect
of the Val/Met SNP on enzyme activity in two ethnic
populations, African Americans and whites (F[2,96]p
; ) (ﬁg. 3). The effects are similar; there was6.55 P ! .01
no signiﬁcant effect of race ( ; )F[1,97]p 1.662 P 1 .05
(table 2) and no signiﬁcant interaction between the Val/
Met genotype and race ( ; ) (tableF[2,96]p 0.389 P 1 .05
3), which suggests that the different haplotypes within
COMT that differentiate these populations (DeMille et
al. 2002) do not impact the Val/Met effect.
Validation of the Val/Met Effect by Use of In Vitro
Translation and Site-Directed Mutagenesis
To further characterize the differential Val/Met effect,
we synthesized MB-COMT-Val and MB-COMT-Met by
use of an in vitro protein synthesis system. We tested the
thermostability of the COMT proteins, and the results
showed that MB-COMT-Val and MB-COMT-Met re-
sponded differently to heat pretreatment at 37C
( ; ) (ﬁg. 4). The ratio of the en-F[1,28]p 23.57 P ! .001
zyme activity between the heat-treated and cold-treated
MB-COMT-Met decreased signiﬁcantly as the duration
of heat treatment increased; however, this effect was not
detected in MB-COMT-Val samples. Thus, there was an
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Figure 3 Effect of the Val/Met genotype on COMT activity in human postmortem DLPFC tissue from two different populations (African
Americans and whites). The effects of the Val/Met genotype in African Americans (A) and whites (B) were similar. N p sample size. One
asterisk (*) indicates difference from Val/Val at a signiﬁcance level of ; two asterisks (**) indicate difference from Val/Val at a signiﬁcanceP ! .05
level of .P ! .001
interaction between genotype and time ( ;F[4,25]p 3.18
). MB-COMT-Val was signiﬁcantly more stableP ! .05
than MB-COMT-Met, as has been shown elsewhere for
S-COMT (Lotta et al. 1995). Thismight represent amech-
anism that underlies the protein and activity differences
in the brains of subjects with the Val and Met genotypes.
Comparison of the human andmouse cDNA sequences
revealed that the mouse has leucine (Leu) at the Val/Met
position of the human COMT protein (ﬁg. 5A). To ex-
plore the potential consequence of this mutation in evo-
lution, we synthesized the soluble form of human and
mouse COMT proteins by use of the in vitro translation
system and analyzed the activity of the synthesized pro-
teins (ﬁg. 5B). There were dramatic differences in enzyme
activity between these variant COMTs (F[2,6]p
; ); the mouse COMT-Leu had much128.19 P ! .0001
higher activity than the human COMTs, and the human
COMT-Val had greater activity than COMT-Met. Be-
cause the Val allele appears to be the ancestral human
allele found in primates (Palmatier et al. 2004), these var-
ious observations suggest that the mutations from Leu to
Val to Met at this polymorphic site in the COMT gene
resulted in progressively lower COMT activity. To further
conﬁrm the importance of the amino acid at this poly-
morphic site, we introduced human Val and Met muta-
tions into the mouse COMT gene by use of a PCR-based
mutagenesis procedure and synthesized the wild-type and
mutant mouse COMT proteins by use of the in vitro
synthesis system (ﬁg. 6A). The results again indicate that
the human Val or Met mutations at the Leu site dra-
matically decreased the activity of the COMT proteins
( ; ) (ﬁg. 6B).F[2,6]p 265.08 P ! .0001
Effect of the P2 Promoter SNP on COMT Activity
A small effect of the SNP in the P2 promoter region
was detected in the DLPFC samples from the African
American subjects, but this effect was not statistically
signiﬁcant ( ; ) (ﬁg. 7A). ToF[2,62] p 1.465 Pp .24
avoid potential confounders from postmortem tissues,
including the possibility that alleles might show differ-
ential postmortem stability, we analyzed the effect of
differences in genotype at this SNP in lymphocyte cul-
tures (ﬁg. 7B). In the lymphocytes, differences in ge-
notype had a statistically signiﬁcant effect (F[2,43]p
; ) (table 2); the P2 promoter SNP effect7.313 P ! .01
was also found in individuals homozygous for Met. A
Western blot analysis of the COMT protein in lympho-
cytes conﬁrmed abundant expression of the MB form of
the protein (ﬁg. 7C), which would be under the control
of the P2 promoter.
Effects of Other SNPs on COMT Activity
The 3′ ﬂanking SNP near the polyadenylation site has
been reported to be strongly associated with schizophre-
nia and to affect differential expression of Val/Met al-
leles (Shifman et al. 2002; Bray et al. 2003). We found
no signiﬁcant effects of this SNP on mRNA or protein
expression or on COMT activity in DLPFC tissue in
the entire sample or in each Val/Met genotype group
( ; ) (table 2). The intron 1 SNPF[2,100]p 1.70 P 1 .05
has also been identiﬁed and linked to risk for schizo-
phrenia, as well as to differential expression of Val/Met
alleles (Shifman et al. 2002; Bray et al. 2003). However,
differences in genotype at this SNP appeared to have no
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Figure 4 Comparison of the ratio of the enzyme activity between
the heat-treated and cold-treated MB-COMT-Met and MB-COMT-
Val. MB-COMT-Val is more stable thanMB-COMT-Met at 37C. The
ratios ( SE) of COMT activity in the synthesized MB-COMT-Val
and MB-COMT-Met samples exposed to a temperature of 37C for
0–120 min (H) or kept on ice at 4C (C), measured in triplicate. One
asterisk (*) indicates difference from COMT-Met at a signiﬁcance level
of ; two asterisks (**) indicate difference fromMB-COMT-MetP ! .05
at a signiﬁcance level of .P ! .01
Table 3
Interaction between Genotype and Sex and Race
MEASUREMENT
INTERACTION (F) BETWEEN
Val/Met and P2 Promoter and 3′ SNP and Intron 1 SNP and
Sex Race Sex Race Sex Race Sex Race
COMT enzyme activity (DLPFC) .04 .39 .08 .46 .06 .4 1.19 2.27
COMT enzyme activity (lymphocytes) 5.32a NAb 1.51 NAb .03 NAb 1.27 NAb
S-COMT immunoreactivity .36 .88 .33 .32 1.32 .92 .49 .51
MB-COMT immunoreactivity .62 .06 1.32 .65 1.55 1.71 .16 .33
COMT mRNA levels .03 1.96 .62 2.67 .77 1.33 .48 1.69
NOTE.—The results of two-way ANOVAs. NA p not applicable.
a .P ! .05
b Only whites were tested.
effect on COMTmRNA or protein expression or enzyme
activity in DLPFC in the entire sample (F[2,100]p
; ) (table 2) or in each Val/Met genotype group0.57 P 1 .5
( ; ). Finally, because of the possi-F[4,94]p 0.50 P 1 .5
bility that COMT activity or the Val/Met effect could be
modiﬁed by a cis-acting haplotype, we constructed likely
haplotypes in our samples on the basis of our four poly-
morphisms by use of SNPHAP, version 1.0 (see the Soft-
ware and Course Materials Web site), and we reanalyzed
COMT activity in the brain on the basis of the common
haplotypes. No effects were seen other than those attrib-
utable to the Val/Met polymorphism (table 2).
Effect of Sex on COMT Activity
Estrogen has been shown to be a regulator of COMT
promoter activity, and COMT activity in blood is lower
in females (Weinshilboum et al. 1999). To test the effects
of sex on COMT activity, we analyzed enzyme activity
of the DLPFC samples from females and males (ﬁg. 8).
The results showed that females have lower COMT ac-
tivity than males ( ; ) (ﬁg. 8A),F[1,106] p 3.96 P ! .05
and the effect of sex was independent of the Val/Met
effect in the DLPFC (ﬁg. 8B). There was no effect of sex
on COMT activity in lymphocytes ( ;F[1,43] p 0.58
) (table 2). However, the interaction between sexP 1 .05
and the Val/Met genotype was signiﬁcant in lymphocytes
( ; ) (table 3), indicating that theF[1,43]p 5.32 P ! .05
effect of genotype was more pronounced in males than
in females.
Discussion
The major ﬁndings of this study are (1) the conﬁrmation
of earlier work that suggested that the Val/Met SNP in
the human COMT gene is a critical genetic factor in de-
termining variation in COMT enzyme activity and (2) the
demonstration that this effect is germane to human
DLPFC at normal physiological temperature. COMT ac-
tivity assayed using standard laboratory methods in post-
mortem DLPFC is ∼40% higher in human subjects with
the COMT-Val allele than in those with the COMT-Met
allele. Similar results were conﬁrmed in lymphocytes by
use of the same assay, which indicates that the ﬁndings
in postmortem tissue are not artifacts of potential differ-
ences in postmortem protein stability related to genotype.
Our data represent the ﬁrst demonstration that there is a
signiﬁcant difference in COMT enzyme activity in the
human brain and, speciﬁcally, that there is a signiﬁcant
difference between the Val and Met genotypes in the
DLPFC. Our results also demonstrate that MB-COMT-
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Figure 5 Comparison of the human and mouse cDNA sequences and COMT activity from three assays. The activity of mouse COMT-
Leu is higher than that of human COMT-Val and COMT-Met. S-COMT proteins from human COMT-Val and COMT-Met, as well as mouse
COMT-Leu, were synthesized using an in vitro transcription-coupled transcription system with 35S-methionine as a radioactive substrate. A,
Representative autoradiogram of the synthesized proteins with radioactive 35S-methionine residue and the amino acid sequences of the three
COMT proteins. B, Averaged COMT activity from three independent assays, normalized with the radioactivity of the 35S-labeled COMT
proteins. The activity of mouse COMT-Leu is signiﬁcantly higher than that of human COMT-Val or COMT-Met. Two asterisks (**) indicate
difference from mouse COMT-Leu at a signiﬁcance level of .P ! .0001
Val appears to show higher stability than MB-COMT-
Met at 37C. Analyses of the human Val and Met sites
and the mouse Leu site reveal a pattern of progressively
lower COMT enzyme activity in the course of these evo-
lutionary changes. Although a SNP in intron 1 and an-
other in the 3′ ﬂanking region have been associated with
a greater risk for schizophrenia and with differential ex-
pression of Val andMet chromosomes in an in vitro assay,
these SNPs—alone or in combination—showed no sig-
niﬁcant effects on COMT mRNA expression levels, pro-
tein immunoreactivity, or enzyme activity in DLPFC or
on enzyme activity in lymphocytes. Thus, although we
cannot rule out a more complex genetic basis for func-
tional effects of COMT, we doubt that the evidence based
on differential expression assays (Bray et al. 2003) trans-
lates into functional changes in COMTprotein expression
or enzyme activity in tissue.
The Mechanism of the Val/Met Effect
The amino acid at the Val/Met polymorphism site has
been localized to the surface of the protein by analysis
of the crystal structure of COMT (Vidgren et al. 1994;
Zubieta et al. 2001). Protein engineering studies have
shown that an enzyme is more stable if it has a more
hydrophobic amino acid residue on its surface (Liu and
Wang 2003; Machius et al. 2003). Since the Val residue
is more hydrophobic than Met, it would be predicted
that Val would be more stable than Met. Our protein
measurements also support this prediction. Likewise,
since Leu is more hydrophobic than Val and Met, it
would be predicted that mouse COMT-Leu would be
more stable than human COMT-Val and COMT-Met.
Indeed, our results are consistent with these predictions
and with a recent study that measured COMT im-
munoreactivity in cell culture and in liver and found
similar differences between the Val and Met alleles
(Shield et al. 2004). However, the sequence homology
between mouse and human COMT proteins is only
∼76%. Thus, the difference in COMT activity between
mouse and human COMT proteins is probably not
solely due to the Val/Met polymorphism site. The dif-
ference in enzyme activity between human COMT-Val
and COMT-Met is ∼40% in our assay, which is much
lower than the 2–4-fold differences reported by other
groups (Weinshilboum and Raymond 1977; Scanlon et
al. 1979; Lotta et al. 1995). Heat pretreatment has been
used to test the thermostability of Val and Met in many
studies, and the remaining COMT activities after heat
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Figure 6 Comparison of the activity of the proteins in mouse COMT-Leu, COMT-Met, and COMT-Val. Mutations from Leu to Val and
Met in mouse COMT resulted in a dramatic reduction in COMT activity. The Leu codon in mouse COMT cDNA was mutated into Val or
Met by site-directed mutagenesis, and the wild-type and mutant mouse COMT proteins were synthesized using an in vitro protein synthesis
system. A, Representative autoradiogram of the wild-type and mutant mouse S-COMT proteins labeled with 35S-methionine and partial protein
sequences. B, Averaged COMT activity from three independent assays, normalized with COMT protein levels. COMT activity differs signiﬁcantly
between the wild-type and mutant proteins. Two asterisks (**) indicate difference from wild-type COMT-Leu at a signiﬁcance level of P !
..0001
pretreatment were then used to calculate the differences
between these alleles. Since we did not use heat pre-
treatment to estimate the COMT activity difference in
the DLPFC samples, the 40% difference for prefrontal
COMT activity may be more representative of the real
difference under normal physiological conditions. How-
ever, we do not know the degree to which our in vitro
assay conditions capture the in vivo functional state of
COMT or the relative contributions of the S and MB
isoforms to overall enzyme activity. Furthermore, we
have no basis for estimating how much total in vivo
activity is retained in the postmortem tissue.
Single SNP Has a Predominant Effect on Final COMT
Activity
Like most human genes, COMT has multiple SNPs.
Among them, the Val/Met SNP is the only common non-
conservative change in a coding regionwith known func-
tion. Our results demonstrate that the effect of the Val/
Met SNP on COMT activity is independent of the three
other SNPs in the COMT gene that have been the subject
of several recent studies. Those SNPs—in the P2 pro-
moter region and in the intron 1 and 3′ ends of the
gene—do not have clear effects independent of their LD
relationship with Val/Met. The possible exception is the
P2 promoter SNP, which was signiﬁcant in the lympho-
cytes of individual homozygotes for the Met or Val al-
leles. It is interesting that our Western blot analysis of
lymphocyte COMT protein indicates that the MB iso-
form is the predominant expressed protein in lympho-
cytes, which would be necessary for variation in the P2
promoter region to effect expression. This is consistent
with an earlier study that also observed MB-COMT ex-
pression in lymphocytes (Sladek-Chelgren and Wein-
shilboum 1981).
We cannot explain previous reports that the intron 1
and 3′ ﬂanking SNPs affect expression of COMT alleles
(Bray et al. 2003). It is conceivable that the allelic ex-
pression approach highlights a biological property of the
gene or of itsmRNA that is not recognized by ourmethod.
However, in the same study that reported these differences
in allelic expression, Val/Met also showed differential al-
lele expression, and the effects of Val/Met and of the other
SNPs were not signiﬁcantly different from each other in
terms of potential transcriptional effects. This ﬁnding by
Bray et al. (2003) is also in conﬂict with that of two other
studies, which examined the effect of the Val/Met geno-
type on the expression level of COMT mRNA and found
no relationship (Matsumoto et al. 2003; Tunbridge et al.
2004b). Our RT-PCR analysis, which represents the larg-
est tissue sample examined to date, also shows no effect.
Clearly, our data suggest that, of the SNPs tested, only
Val/Met and possibly the P2 promoter SNP affect enzyme
activity in cells and tissues. This would seem to be the
critical biological end point of genetic variation in this
gene. However, as stated, we cannot rule out complex
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Figure 7 Effect of the P2 promoter SNP on COMT activity in human DLPFC (A) and lymphoblast cell cultures (B) of different genotypes
at the promoter SNP site. Two asterisks (**) indicate difference from genotype 1/1 at a signiﬁcance level of . Similar effects were seenP ! .01
in lymphocytes of subjects with the homozygous Met/Met genotype. C, Abundant MB-COMT protein, detected by Western blotting with the
use of a speciﬁc anti-human COMT antibody, in lymphocytes (L) and brain (B) protein samples.
genetic effects—for example, cis effects within COMT—
that only operate under speciﬁc conditions (e.g., during
activation of other genes or during speciﬁc developmental
windows). It is also worth emphasizing that our results
do not speak directly to the clinical associationswith these
other SNPs, whichwere reported by Shifman et al. (2002).
The frequencies of the Val and Met alleles are sub-
stantially different among several populations, varying
by as much as 4-fold (DeMille et al. 2002), and multi-
marker haplotypes in COMT also show marked differ-
ences across populations (Palmatier et al. 2004). The
results in our relatively small population samples are
consistent with these earlier data in showing that whites
of European ancestry have a lower frequency of the Val
allele than do African Americans. It is interesting that
we found no difference in the effect of the Val/Met SNP
on COMT activity in these two populations, further sug-
gesting that potential cis effects within COMT, which
might be expected to vary across these populations be-
cause of differences in LD within COMT, do not dilute
the Val/Met effect. Consistent with the study by DeMille
et al. (2002), we also observed that Val chromosomes
predominantly have G alleles at the promoter locus,
whereas Met chromosomes have almost equal frequen-
cies of P2 promoter SNP alleles. This suggests that there
may be two populations of Met alleles with respect to
enzyme activity and that chromosomes with both Met
and P2 promoter A (P2A) alleles would have especially
low COMT activity. Thus, to the extent that the P2A
allele may be the more recent variation at this locus, it
suggests another evolutionary change leading to lower
COMT activity.
Higher Activity of COMT in DLPFC and Increased Risk
for Schizophrenia
Comparative genomics is a useful strategy to elucidate
the biological implications of variations in a gene. By
comparing human COMT with mouse COMT, we con-
ﬁrmed amino acid differences in the polymorphism site
as well as differences in enzyme activity. Mouse COMT
has Leu at the position of Val/Met in human COMT and
ismore active than either humanVal orMet. SinceCOMT
is enriched in liver and plays an important role in chemical
detoxiﬁcation, it might be an advantage for the mouse to
have a highly active version of COMT. Other species such
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Figure 8 Effect of the subject’s sex on COMT activity in human DLPFC. Females had signiﬁcantly lower COMT activity in the samples
as a whole (A) as well as in each of the Val/Met genotypes (B). The asterisk (*) indicates difference from males at a signiﬁcance level of P !
..05
as rabbit and pig also have the Leu codon at this locus
in the COMT gene. However, nonhuman primates carry
the Val allele (Palmatier et al. 2004), which is less active
than Leu but more active than Met. Met appears to be
a unique mutation in the human COMT gene, which has
not been seen thus far in any other species. These obser-
vations suggest that there has been evolutionary pressure
to lower COMT activity, perhaps correlating with the
emergence of higher cortical function. Although the ab-
solute difference in COMT activity between the Val and
Met alleles appears to be relatively small, at least based
on our in vitro assay, this difference may be biologically
critical for regulation of dopamine signaling in prefrontal
cortex (Goldman-Rakic et al. 2004). Those studies that
have shown a positive association between COMT and
schizophrenia have primarily pinpointed the Val allele as
the risk allele (Harrison and Weinberger 2004). Thus,
although our data do not clarify reports that Val alleles
on speciﬁc haplotype backgrounds may account for
greater risk of disease than Val itself (e.g., Shifman et al.
2002), our results do suggest that this putative effect is
not because of simple consequences of additional varia-
tion in COMT protein abundance or enzyme activity.
Therefore, our ﬁndings support the hypothesis that higher
COMT activity results in lower prefrontal dopamine sig-
naling and, by this mechanism, leads to relatively im-
paired prefrontal cortical function and an increased risk
of clinical disorders in which prefrontal cortical function
contributes to disease pathogenesis.
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